| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -11,887 | -5,877 |
| Depreciation expense | 24 | 14 |
| Stock-based compensation expense | 1,864 | 1,134 |
| Change in fair value of warrant liability | -9,789 | -8,722 |
| Amortization of operating lease right of use asset | 397 | 259 |
| Prepaid expense and other current assets | 2,786 | 2,392 |
| Accounts payable and accrued liabilities | -691 | -1,466 |
| Operating lease liability | -417 | -273 |
| Net cash used in operating activities | -23,285 | -17,323 |
| Proceeds from issuance of series b-1 preferred stock | - | 0 |
| Purchases of property and equipment | 24 | 22 |
| Dividends on preferred stock | - | 0 |
| Net cash used in investing activities | -24 | -22 |
| Proceeds from secondary public offering | 39,771 | 12,624 |
| Issuance costs related to issuance of series b-1 preferred stock | - | 0 |
| Commissions paid on secondary public offering | 1,193 | 379 |
| Payments on financed insurance policies | 212 | 211 |
| Proceeds from exercise of warrants | 1,496 | 1,496 |
| Net cash provided by financing activities | 39,862 | 13,530 |
| Net increase in cash and cash equivalents | 16,553 | -3,815 |
| Cash and cash equivalents at beginning of period | 26,142 | - |
| Cash and cash equivalents at end of period | 42,695 | - |
Unicycive Therapeutics, Inc. (UNCY)
Unicycive Therapeutics, Inc. (UNCY)